Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Adult Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA)

NCT02817061
View directory record Official record
Conditions
Disease Type and/or Category Not Applicable
Interventions
Omnilux
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

NCT01509846
View directory record Official record
Conditions
Shigellosis
Interventions
Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study Investigating the Effectiveness of a LifeSeasons NeuroQ Supplement With Lifestyle Changes to Improve Cognitive Function in Healthy Adults Who Have One or More Risk Factors for Cognitive Decline

NCT04149639
View directory record Official record
Conditions
Healthy
Interventions
NeuroQ
Dietary Supplement
Lead sponsor
LifeSeasons Inc.
Industry
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Studio City, California • Flower Mound, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 24, 2026, 4:21 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Deliver-EE: Evaluating Effects of Meal Delivery

NCT05357261
View directory record Official record
Conditions
Healthy
Interventions
Wellness Check and Socialization, Prepared Meals
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
66 Years and older
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
14
States / cities
San Diego, California • Clearwater, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed No phase listed Observational

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

NCT04409561
View directory record Official record
Conditions
Sepsis, Septic Shock, Healthy
Interventions
Blood collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

NCT01605994
View directory record Official record
Conditions
Healthy Adult Normals
Interventions
BMS-933043, Placebo matching with BMS-933043, Antacid Buffer Predose Solution
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

NCT02213354
View directory record Official record
Conditions
Avian Influenza
Interventions
MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years to 99 Years
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

NCT02298842
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Platelets stored in InterSol, Platelets stored in Plasma
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants

NCT06979973
View directory record Official record
Conditions
Healthy
Interventions
Midazolam, Rosuvastatin, CKD-508 Tablet
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

NCT01722669
View directory record Official record
Conditions
Healthy
Interventions
isoquercetin or quercetin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

RDEA3170 Bioavailability Study

NCT02336594
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 10 mg, RDEA3170 2.5 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

NCT01959594
View directory record Official record
Conditions
Healthy
Interventions
3 mg PF-06412562, 10 mg PF-06412562, 25 mg PF-06412562, PF-06412562 TBD mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 24, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ascending Glycan Dietary Supplementation in Healthy Adults

NCT04466761
View directory record Official record
Conditions
Healthy Individuals
Interventions
Monosaccharide Powder, Placebo Comparator
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 24, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Sep 24, 2026, 4:21 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Stanford University Microbiome Bank

NCT07625059
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Microbiome bank
Other
Lead sponsor
Sean Spencer
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

NCT03928327
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-788, Itraconazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 24, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility and Acceptability of Mindful Self-Compassion Among Transgender and Nonbinary Young Adults

NCT06409975
View directory record Official record
Conditions
Healthy
Interventions
Mindful Self-Compassion (MSC)
Behavioral
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

NCT06003777
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06954522, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 24, 2026, 4:21 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 24, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

NCT04908995
View directory record Official record
Conditions
Healthy Adults
Interventions
EC5026 oral tablet, Placebo oral tablet
Drug · Other
Lead sponsor
EicOsis Human Health Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 24, 2026, 4:21 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

NCT07198139
View directory record Official record
Conditions
Norovirus
Interventions
CDI-988, Placebo, Snow Mountain Virus
Drug · Other
Lead sponsor
Cocrystal Pharma, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 24, 2026, 4:21 AM EDT